Utah Medical Products (UTMD)
NASDAQ:UTMD
Want to see UTMD full AI Analyst Report?
UTMD Stock Chart & Stats
$55.67
-$0.06(-0.11%)
At close: 4:00 PM EST
$55.67
-$0.06(-0.11%)
Day’s Range― - ―
52-Week Range$52.00 - $71.81
Previous CloseN/A
Volume4.21K
Average Volume (3M)15.88K
Market Cap
$213.46M
Enterprise Value$121.99M
Total Cash (Recent Filing)$87.41M
Total Debt (Recent Filing)$210.00K
Price to Earnings (P/E)19.7
Beta0.59
Next Earnings
Jul 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.15%
Share Statistics
EPS (TTM)3.30
Shares Outstanding3,184,025
10 Day Avg. Volume20,525
30 Day Avg. Volume15,884
Financial Highlights & Ratios
PEG Ratio-1.18
Price to Book (P/B)1.55
Price to Sales (P/S)4.81
P/FCF Ratio12.93
Enterprise Value/Market Cap0.57
Enterprise Value/Revenue3.25
Enterprise Value/Gross Profit6.06
Enterprise Value/Ebitda7.46
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetNear-zero leverage and sizeable equity provide durable financial flexibility. Over the next 2–6 months this supports capital allocation optionality (R&D, targeted buybacks, dividends, small M&A) and resiliency through procedure-volume cycles without raising material funding risk.
High Margins / ProfitabilitySustained high gross and net margins reflect proprietary devices and recurring consumable sales, enabling durable profit generation. These margins support strong returns and buffer short-term revenue softness, preserving cash available for reinvestment and shareholder returns over several quarters.
Strong Cash ConversionVery high cash conversion means accounting earnings largely translate to cash, enabling reliable internal funding of operations and distributions. Even with a recent directional decline, near-parity FCF supports near-term liquidity and lowers refinancing or external funding needs.
Bears Say
Persistent Revenue DeclineA multi-year top-line contraction reduces operating leverage and constrains long-term growth prospects. Persistent revenue declines can erode scale advantages, pressure R&D and commercial investment, and make it harder to sustain revenue-dependent margins across the next several quarters.
Softening Free Cash Flow TrendWhile conversion remains high, a declining FCF trend limits the company's ability to increase discretionary spends (marketing, new product launches) or pursue larger acquisitions. Continued FCF compression over months would reduce optionality and could force tougher capital-allocation tradeoffs.
Narrow Product Focus / Market ConcentrationConcentration in women’s health and neonatal niches limits total addressable market and ties revenue to procedure volumes and hospital purchasing patterns. This specialization increases exposure to competitive or reimbursement shifts and slows diversification possibilities over the medium term.
Utah Medical Products News
UTMD FAQ
What was Utah Medical Products’s price range in the past 12 months?
Utah Medical Products lowest stock price was $52.00 and its highest was $71.81 in the past 12 months.
What is Utah Medical Products’s market cap?
Utah Medical Products’s market cap is $213.46M.
When is Utah Medical Products’s upcoming earnings report date?
Utah Medical Products’s upcoming earnings report date is Jul 28, 2026 which is in 37 days.
How were Utah Medical Products’s earnings last quarter?
Utah Medical Products released its earnings results on Apr 23, 2026. The company reported $0.818 earnings per share for the quarter, beating the consensus estimate of N/A by $0.818.
Is Utah Medical Products overvalued?
According to Wall Street analysts Utah Medical Products’s price is currently Overvalued.
Does Utah Medical Products pay dividends?
Utah Medical Products pays a Quarterly dividend of $0.31 which represents an annual dividend yield of 2.15%. See more information on Utah Medical Products dividends here
What is Utah Medical Products’s EPS estimate?
Utah Medical Products’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Utah Medical Products have?
Utah Medical Products has 3,184,025 shares outstanding.
What happened to Utah Medical Products’s price movement after its last earnings report?
Utah Medical Products reported an EPS of $0.818 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -2.528%.
Which hedge fund is a major shareholder of Utah Medical Products?
Currently, no hedge funds are holding shares in UTMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Utah Medical Products Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
UTMD Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 78.1K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-5.23%
12-Months-Change
Fundamentals
Return on Equity
9.13%
Trailing 12-Months
Asset Growth
1.52%
Trailing 12-Months
Company Description
Utah Medical Products
Utah Medical Products, Inc. (UTMD) is a healthcare technology company focused on the creation, production, and supply of medical devices for the healthcare sector. UTMD offers a comprehensive portfolio of medical devices primarily serving labor and delivery departments and neonatal intensive care units. Key offerings include fetal monitoring accessories, vacuum-assisted delivery systems, and other specialized tools for childbirth. For newborns, they provide respiratory hoods (DISPOSA-HOOD), umbilical vessel catheters (GESCO), silicone oral protection devices (PALA-NATE), and lumbar sampling kits (MYELO-NATE). Beyond maternity care, the company supplies blood pressure monitoring systems (DELTRAN PLUS), disposable peritoneal dialysis sets (DIALY-NATE), urinary drainage systems (URI-CATH), and feeding devices (NUTRI-CATH/NUTRI-LOK). They also manufacture HEMO-NATE disposable filters, various catheterization procedure trays, and DELTRAN disposable pressure transducers along with related accessories and molded parts. A substantial portion of UTMD's offerings targets women's health and gynecological interventions. This includes advanced electrosurgical solutions like the LETZ system for cervical lesion excision, paired with FINESSE+ generators and various specialized electrodes (loop, ball, needle), and FILTRESSE evacuators. They also provide laparoscopic instruments (Femcare line), including trocars and cannulae, alongside EPITOME and OptiMicro electrosurgical devices. Complementing these are products for surgical contraception (Filshie Clip), endoscopic irrigation (PATHFINDER PLUS), suprapubic catheterization, and urinary incontinence management (LIBERTY systems). Specialized tools for uterine assessment and sampling, such as the ENDOCURETTE and TVUS/HSG-Cath, as well as the LUMIN uterine manipulator for laparoscopic procedures, complete this extensive portfolio. UTMD's diverse product range serves various healthcare settings, including neonatal intensive care units, labor and delivery wards, women's health centers within hospitals, outpatient clinics, and physicians' offices. The company facilitates distribution through a combination of direct customer service and sales teams, independent consultants, and manufacturer representatives. Established in 1978, Utah Medical Products, Inc. maintains its headquarters in Midvale, Utah.
Technical Analysis
Ownership Overview
0.69% Insiders
17.18% Mutual Funds
27.37% Other Institutional Investors
42.48% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---